A study to determine the seroprevalence of Bordetella pertussis in adults in Hungary
Trial overview
Number of seropositive subjects in terms of anti-pertussis toxin (anti-PT) concentrations
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels strongly indicative of current/recent infection
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels indicative of current/recent infection
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seronegative subjects in terms of anti-PT concentrations
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seropositive subjects in terms of anti-PT concentrations (by age)
Timeframe: At the time of enrollment of each subject (Day 0).
Number of subjects with anti-PT IgG levels strongly indicative of current/recent infection (by age)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels indicative of current/recent infection (by age)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seronegative subjects in terms of anti-PT concentrations (by age)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seropositive subjects in terms of anti-PT concentrations (by gender)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels strongly indicative of current/recent infection (by gender)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels indicative of current/recent infection (by gender)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seronegative subjects in terms of anti-PT concentrations (by gender)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels not indicative of current/recent infection (by gender)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seropositive subjects in terms of anti-PT concentrations (by recent history of long-lasting cough)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seronegative subjects in terms of anti-PT concentrations (by recent history of long-lasting cough)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels indicative of current/recent infection (by recent history of long-lasting cough)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels not indicative of current/recent infection (by recent history of long-lasting cough)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seropositive subjects in terms of anti-PT concentrations (by smoking status)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seronegative subjects in terms of anti-PT concentrations (by smoking status)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels indicative of current/recent infection (by smoking status)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels not indicative of current/recent infection (by smoking status)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seropositive subjects in terms of anti-PT concentrations (by history of pertussis)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seronegative subjects in terms of anti-PT concentrations (by history of pertussis)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels indicative of current/recent infection (by history of pertussis)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels not indicative of current/recent infection (by history of pertussis)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seropositive subjects in terms of anti-PT concentrations (by history of vaccination against pertussis)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seronegative subjects in terms of anti-PT concentrations (by history of vaccination against pertussis)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels indicative of current/recent infection (by history of vaccination against pertussis)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels not indicative of current/recent infection (by history of vaccination against pertussis)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seropositive subjects in terms of anti-PT concentrations (by medication)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seronegative subjects in terms of anti-PT concentrations (by medication)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels indicative of current/recent infection (by medication)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels not indicative of current/recent infection (by medication)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seropositive subjects in terms of anti-PT concentrations (by hospitalization)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of seronegative subjects in terms of anti-PT concentrations (by hospitalization)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels indicative of current/recent infection (by hospitalization)
Timeframe: At the time of enrollment of each subject (Day 0)
Number of subjects with anti-PT IgG levels not indicative of current/recent infection (by hospitalization)
Timeframe: At the time of enrollment of each subject (Day 0)
Participation criteria
- Subjects who the investigator believes can and will comply with the requirements of the protocol.
- Written informed consent will be obtained from subjects prior to performing any study procedures.
- Confirmed or suspected immunological disorder.
- Written informed consent will be obtained from subjects prior to performing any study procedures.
- Males or females ≥ 18 years of age at the time of enrollment.
- Agreeing to collection of a blood sample for the study.
Subjects who the investigator believes can and will comply with the requirements of the protocol.
Confirmed or suspected immunological disorder.
Trial location(s)
Study documents
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.